{"name":"Magistra GLP-1 Safety & Efficacy Database","version":"1.0","lastUpdated":"2026-10-30","totalEffectsTracked":15,"totalDataPoints":3519,"evidentiaryBase":{"corpusPoints":3669,"ratePoints":2612,"eligibleRates":1961,"distinctSources":89,"sourceEntries":614,"seriousAeSourceEntries":10,"drugMix":[{"drug":"orforglipron","statedRates":952,"distinctStudies":15,"sourceEntries":126},{"drug":"semaglutide","statedRates":361,"distinctStudies":34,"sourceEntries":228},{"drug":"tirzepatide","statedRates":257,"distinctStudies":13,"sourceEntries":123},{"drug":"liraglutide","statedRates":143,"distinctStudies":14,"sourceEntries":93},{"drug":"dulaglutide","statedRates":112,"distinctStudies":12,"sourceEntries":84},{"drug":"retatrutide","statedRates":60,"distinctStudies":1,"sourceEntries":10},{"drug":"lixisenatide","statedRates":43,"distinctStudies":8,"sourceEntries":41},{"drug":"exenatide","statedRates":29,"distinctStudies":5,"sourceEntries":24},{"drug":"(unlabelled)","statedRates":4,"distinctStudies":3,"sourceEntries":3}],"drugMixNote":"Which molecules the rows behind this estimate describe. statedRates counts eligible rate rows — the same n published beside the estimate — and pooledWeightPct is the share of the weighted mean that drug's collapsed source entries actually carry, after one-entry-per-source collapsing and sample-size weighting; an entry holding two molecules' rows (a head-to-head trial's arms) splits its weight by row share, since its rate is the plain mean of those rows (corrected 2026-09-23: until then the whole entry went to one arm's molecule, publishing SURPASS-CVOT's dulaglutide arm as tirzepatide). The two diverge widely: a drug can hold most of the rows and little of the weight when its rows are many small arms of a few trials. Read pooledWeightPct for what moves the percentage and statedRates for what the n is made of. Per-drug distinctStudies can sum above this estimate's own distinctSources — a trial with a comparator arm posts rows under two molecules and counts once under each. The drug is the one the row's own arm or source names; \"(unlabelled)\" is a row whose source names no molecule. At site-wide scope only the counts are published: there is no site-wide pooled rate, so no weight share of one is meaningful. See rateBase.clinical.drugMix on ?q=effect&id=<id> for pooledWeightPct beside the estimate it describes.","indicationMix":[{"indication":"obesity","statedRates":920,"distinctStudies":26,"sourceEntries":243},{"indication":"t2d","statedRates":722,"distinctStudies":44,"sourceEntries":283},{"indication":"other","statedRates":211,"distinctStudies":6,"sourceEntries":29},{"indication":"cvot","statedRates":56,"distinctStudies":7,"sourceEntries":40},{"indication":"t1d_adjunct","statedRates":45,"distinctStudies":2,"sourceEntries":15},{"indication":"(unspecified)","statedRates":7,"distinctStudies":4,"sourceEntries":4}],"indicationMixNote":"Which population the rows behind this estimate were trialled in, read from each ClinicalTrials.gov record (re-read for every stored registry study on 2 October 2026): obesity/overweight (obesity, including Phase 1 studies in healthy volunteers with obesity), type 2 diabetes (t2d), a cardiovascular-outcomes trial whose registered primary outcome is a composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke, ELIXA adding unstable-angina hospitalisation (cvot: ELIXA, LEADER, REWIND, SUSTAIN-6, SELECT, SOUL, SURPASS-CVOT — their participants had type 2 diabetes with established cardiovascular disease or high cardiovascular risk or, in SELECT, established cardiovascular disease with overweight or obesity and without diabetes), type 1 diabetes as an adjunct to insulin (t1d_adjunct), or other (healthy-volunteer, Alzheimer's disease and kidney-disease studies). statedRates counts eligible rate rows; pooledWeightPct is the share of the weighted mean that indication's collapsed source entries carry, after one-entry-per-source collapsing and sample-size weighting (same method as drugMix). Read pooledWeightPct, not the row counts: the outcomes trials are few but very large, and carry most of the weight behind the common gastrointestinal estimates (63% for nausea on 2 October 2026). \"(unspecified)\" is the few eligible rows from non-registry sources, which state no structured conditions. The rates themselves are read correctly from the registry regardless of indication; this field discloses composition, it does not change eligibility or weighting. At site-wide scope only the counts are published, for the same reason drugMix strips its weight share here. See rateBase.clinical.indicationMix on ?q=effect&id=<id> for pooledWeightPct beside the estimate it describes.","windowMix":[{"window":"<=26w","statedRates":794,"distinctStudies":15,"sourceEntries":88},{"window":"27-52w","statedRates":355,"distinctStudies":18,"sourceEntries":113},{"window":"53-104w","statedRates":591,"distinctStudies":34,"sourceEntries":286},{"window":">104w","statedRates":158,"distinctStudies":14,"sourceEntries":95},{"window":"(window not stated)","statedRates":63,"distinctStudies":8,"sourceEntries":32}],"medianWindowWeeks":57,"windowMixNote":"Over which counting window the rows behind this estimate were recorded, read from each trial registry record's own adverse-event time frame: <=26 weeks, 27-52, 53-104, or over 104. statedRates counts eligible rate rows and pooledWeightPct is the share of the weighted mean each window's collapsed source entries carry (same method as drugMix). A registry rate is the share of an arm with the event at least once within that trial's window, so the window changes the number: short Phase 1 studies supply many rows but little weight, and most of the weight on most effects comes from trials of a year or longer. medianWindowWeeks is the median window across the distinct studies that state one; a record stating several windows (e.g. different arms followed for different lengths) is filed under the longest. \"(window not stated)\" covers every non-registry source and the registry records that post no adverse-event time frame; it is never read as zero weeks. This field discloses composition; it does not change eligibility or re-weight anything. At site-wide scope only the counts are published, for the same reason drugMix strips its weight share here. See rateBase.clinical.windowMix on ?q=effect&id=<id> for pooledWeightPct beside the estimate it describes.","thresholdMix":{"seriousTableRows":18,"atLeast5PctThresholdRows":1591,"allEventRows":345,"otherThresholdRows":0,"notStatedRows":7},"thresholdNote":"Which listing threshold the trials behind this estimate used for their non-serious adverse-event table. Most of the registry trials we pool list a non-serious event only when it exceeded 5% in at least one arm (atLeast5PctThresholdRows); some list every event (allEventRows). A trial in which a term stayed at or under 5% in every arm contributes no row for it, so for effects pooled near or below 5% the base can mostly include only trials where the term was listed: the count of trials is a floor on how many trials saw the effect, and the pooled rate is likely higher than it would be across all trials. Rows read from a serious adverse-events table carry no such threshold and are counted apart (seriousTableRows). notStatedRows are non-registry sources (e.g. published abstracts), which state no listing threshold. Counts are eligible rate rows, the same n published beside the estimate.","excluded":{"seed_unverified":150,"no_rate":1057,"spontaneous_report_share":66,"aggregator_result":14,"placebo_comparator_arm":421},"note":"Both corpusPoints and totalDataPoints are scoped to the 15 publicly-tracked effects (excluding kidney_issues/muscle_loss/weight_regain, extraction-only categories never displayed on the site); they differ only in that corpusPoints includes the April-2026 seed points retained for audit trail and totalDataPoints excludes them. Corrected 2026-09-11: until then totalDataPoints and dataPointsBySource were computed from an unscoped metadata blob, so this response published a corpus total 97 higher than the sum of its own dataPointsByEffect — totalDataPoints read 1,901 where the scoped figure is 1,804. Of the corpus, only ratePoints state a rate; after eligibility rules, eligibleRates are allowed to support a published estimate. distinctSources counts distinct STUDIES by source URL with its fragment stripped (a registry record or paper counts once however many effects it reports; re-keyed 2026-09-08 — until then this field counted one entry per source per effect, now exposed as sourceEntries). Per-effect breakdown: ?q=effect&id=<effect>, field rateBase, whose distinctSources is keyed the same way (re-keyed 2026-09-10 — it too counted one entry per source per effect until then, and still does under sourceEntries; the two differ only where one study posts more than one MedDRA preferred term for the same effect, e.g. SURMOUNT-1's Pancreatitis and Pancreatitis acute)."},"demographicCoverage":{"sexStated":138,"sexStatedCommunity":127,"ageRangeStated":122,"ageRangeStatedCommunity":97,"of":3519,"note":"Points carrying an extracted sex (not 'unspecified') or age range, over the same scoped set as totalDataPoints. Mostly community self-reports; the remainder are trial and news rows that state a sex or age band."},"intakeAndExclusions":{"intake":{"runs":202,"firstRun":"2026-04-07","lastRun":"2026-10-30","daysWithoutReport":5,"cumulative":{"scrapedItems":70026,"extractedRows":19182,"newStored":4147,"duplicateRows":15035},"latest":{"date":"2026-10-30","scrapedItems":378,"extractedRows":143,"newStored":21,"duplicateRows":122,"itemsWithFinding":109,"drops":{"itemsNoFinding":269,"itemsAllRowsGated":0,"itemsExtractionError":0,"effectGateRejectedRows":0,"drugGateRejectedRows":0,"duplicateRows":122},"scraperFailed":[],"bySource":{"PubMed":{"scraped":35,"itemsWithFinding":4,"itemsNoFinding":31,"itemsAllRowsGated":0,"itemsExtractionError":0,"effectGateRejectedRows":0,"drugGateRejectedRows":0,"extractedRows":5,"duplicateRows":4,"newStored":1},"Scholar":{"scraped":0,"itemsWithFinding":0,"itemsNoFinding":0,"itemsAllRowsGated":0,"itemsExtractionError":0,"effectGateRejectedRows":0,"drugGateRejectedRows":0,"extractedRows":0,"duplicateRows":0,"newStored":0},"Reddit":{"scraped":0,"itemsWithFinding":0,"itemsNoFinding":0,"itemsAllRowsGated":0,"itemsExtractionError":0,"effectGateRejectedRows":0,"drugGateRejectedRows":0,"extractedRows":0,"duplicateRows":0,"newStored":0},"FDA":{"scraped":105,"itemsWithFinding":59,"itemsNoFinding":46,"itemsAllRowsGated":0,"itemsExtractionError":0,"effectGateRejectedRows":0,"drugGateRejectedRows":0,"extractedRows":59,"duplicateRows":59,"newStored":0},"News":{"scraped":23,"itemsWithFinding":0,"itemsNoFinding":23,"itemsAllRowsGated":0,"itemsExtractionError":0,"effectGateRejectedRows":0,"drugGateRejectedRows":0,"extractedRows":0,"duplicateRows":0,"newStored":0},"India":{"scraped":24,"itemsWithFinding":1,"itemsNoFinding":23,"itemsAllRowsGated":0,"itemsExtractionError":0,"effectGateRejectedRows":0,"drugGateRejectedRows":0,"extractedRows":1,"duplicateRows":1,"newStored":0},"Trials":{"scraped":57,"itemsWithFinding":20,"itemsNoFinding":37,"itemsAllRowsGated":0,"itemsExtractionError":0,"effectGateRejectedRows":0,"drugGateRejectedRows":0,"extractedRows":20,"duplicateRows":0,"newStored":20},"MHRA":{"scraped":15,"itemsWithFinding":6,"itemsNoFinding":9,"itemsAllRowsGated":0,"itemsExtractionError":0,"effectGateRejectedRows":0,"drugGateRejectedRows":0,"extractedRows":21,"duplicateRows":21,"newStored":0},"YouTube":{"scraped":0,"itemsWithFinding":0,"itemsNoFinding":0,"itemsAllRowsGated":0,"itemsExtractionError":0,"effectGateRejectedRows":0,"drugGateRejectedRows":0,"extractedRows":0,"duplicateRows":0,"newStored":0},"Cochrane":{"scraped":10,"itemsWithFinding":1,"itemsNoFinding":9,"itemsAllRowsGated":0,"itemsExtractionError":0,"effectGateRejectedRows":0,"drugGateRejectedRows":0,"extractedRows":1,"duplicateRows":1,"newStored":0},"Guidelines":{"scraped":20,"itemsWithFinding":0,"itemsNoFinding":20,"itemsAllRowsGated":0,"itemsExtractionError":0,"effectGateRejectedRows":0,"drugGateRejectedRows":0,"extractedRows":0,"duplicateRows":0,"newStored":0},"WHO":{"scraped":15,"itemsWithFinding":4,"itemsNoFinding":11,"itemsAllRowsGated":0,"itemsExtractionError":0,"effectGateRejectedRows":0,"drugGateRejectedRows":0,"extractedRows":6,"duplicateRows":6,"newStored":0},"EMA":{"scraped":15,"itemsWithFinding":2,"itemsNoFinding":13,"itemsAllRowsGated":0,"itemsExtractionError":0,"effectGateRejectedRows":0,"drugGateRejectedRows":0,"extractedRows":4,"duplicateRows":4,"newStored":0},"DrugsReviews":{"scraped":18,"itemsWithFinding":11,"itemsNoFinding":7,"itemsAllRowsGated":0,"itemsExtractionError":0,"effectGateRejectedRows":0,"drugGateRejectedRows":0,"extractedRows":25,"duplicateRows":25,"newStored":0},"Preprints":{"scraped":0,"itemsWithFinding":0,"itemsNoFinding":0,"itemsAllRowsGated":0,"itemsExtractionError":0,"effectGateRejectedRows":0,"drugGateRejectedRows":0,"extractedRows":0,"duplicateRows":0,"newStored":0},"Quora":{"scraped":20,"itemsWithFinding":1,"itemsNoFinding":19,"itemsAllRowsGated":0,"itemsExtractionError":0,"effectGateRejectedRows":0,"drugGateRejectedRows":0,"extractedRows":1,"duplicateRows":1,"newStored":0},"Twitter":{"scraped":6,"itemsWithFinding":0,"itemsNoFinding":6,"itemsAllRowsGated":0,"itemsExtractionError":0,"effectGateRejectedRows":0,"drugGateRejectedRows":0,"extractedRows":0,"duplicateRows":0,"newStored":0},"Trustpilot":{"scraped":15,"itemsWithFinding":0,"itemsNoFinding":15,"itemsAllRowsGated":0,"itemsExtractionError":0,"effectGateRejectedRows":0,"drugGateRejectedRows":0,"extractedRows":0,"duplicateRows":0,"newStored":0}}},"runsWithDropDetail":26,"reconciliation":{"storedBeforeFirstRun":26,"storedAfterLastRun":3884,"netChangeOutsideDailyRuns":-289}},"storage":{"stored":3884,"counted":3519,"excluded":{"seed_unverified":150,"off_taxonomy":215},"offTaxonomyByEffect":{"weight_regain":66,"muscle_loss":46,"kidney_issues":16,"temperature_dysregulation":86,"menstrual_irregularity":1}},"pooling":{"byEffect":[{"effect":"nausea","clinicalTrackRows":388,"pooled":251,"excluded":{"seed_unverified":3,"spontaneous_report_share":8,"no_rate":69,"placebo_comparator_arm":57},"communityTrackRows":173},{"effect":"diarrhea","clinicalTrackRows":344,"pooled":238,"excluded":{"seed_unverified":3,"spontaneous_report_share":8,"no_rate":43,"placebo_comparator_arm":52},"communityTrackRows":84},{"effect":"constipation","clinicalTrackRows":297,"pooled":220,"excluded":{"seed_unverified":3,"spontaneous_report_share":5,"no_rate":25,"placebo_comparator_arm":44},"communityTrackRows":76},{"effect":"reduced_appetite","clinicalTrackRows":281,"pooled":214,"excluded":{"seed_unverified":3,"spontaneous_report_share":5,"no_rate":16,"placebo_comparator_arm":43},"communityTrackRows":51},{"effect":"headache","clinicalTrackRows":260,"pooled":199,"excluded":{"seed_unverified":3,"spontaneous_report_share":4,"no_rate":10,"placebo_comparator_arm":44},"communityTrackRows":23},{"effect":"pancreatitis","clinicalTrackRows":39,"pooled":13,"excluded":{"seed_unverified":3,"spontaneous_report_share":2,"no_rate":19,"placebo_comparator_arm":2},"communityTrackRows":41},{"effect":"fatigue","clinicalTrackRows":154,"pooled":113,"excluded":{"seed_unverified":3,"spontaneous_report_share":6,"no_rate":8,"placebo_comparator_arm":24},"communityTrackRows":53},{"effect":"vomiting","clinicalTrackRows":350,"pooled":237,"excluded":{"spontaneous_report_share":8,"no_rate":48,"seed_unverified":6,"placebo_comparator_arm":51},"communityTrackRows":94},{"effect":"abdominal_pain","clinicalTrackRows":230,"pooled":173,"excluded":{"spontaneous_report_share":7,"seed_unverified":6,"no_rate":11,"placebo_comparator_arm":33},"communityTrackRows":72},{"effect":"acid_reflux","clinicalTrackRows":114,"pooled":86,"excluded":{"no_rate":9,"seed_unverified":3,"placebo_comparator_arm":16},"communityTrackRows":51},{"effect":"gallstones","clinicalTrackRows":59,"pooled":37,"excluded":{"seed_unverified":3,"no_rate":14,"placebo_comparator_arm":5},"communityTrackRows":45},{"effect":"hair_loss","clinicalTrackRows":42,"pooled":22,"excluded":{"seed_unverified":3,"no_rate":7,"placebo_comparator_arm":10},"communityTrackRows":25},{"effect":"injection_site_reaction","clinicalTrackRows":48,"pooled":20,"excluded":{"spontaneous_report_share":9,"no_rate":8,"seed_unverified":6,"placebo_comparator_arm":5},"communityTrackRows":23},{"effect":"dizziness","clinicalTrackRows":185,"pooled":138,"excluded":{"spontaneous_report_share":4,"seed_unverified":3,"no_rate":5,"placebo_comparator_arm":35},"communityTrackRows":20},{"effect":"emotional_blunting","clinicalTrackRows":4,"pooled":0,"excluded":{"seed_unverified":3,"no_rate":1},"communityTrackRows":43}],"totals":{"clinicalTrackRows":2795,"pooled":1961,"excluded":{"seed_unverified":54,"spontaneous_report_share":66,"no_rate":293,"placebo_comparator_arm":421},"communityTrackRows":874},"reasons":["no_rate","spontaneous_report_share","seed_unverified","placebo_comparator_arm"]},"poolingReasonGloss":{"no_rate":"No rate to pool. Usually the source mentions the effect without stating a percentage. For a smaller number of rows a figure was found but withheld when the row was written, with the reason recorded on the row, for example a placebo or comparator arm, a serious-events-table count, the midpoint of a range, or a figure the source does not state word for word. The row still records the mention.","spontaneous_report_share":"An FDA FAERS figure: a term's share of the reaction terms reported for a drug, not an incidence rate. Published separately per effect, never averaged into a rate.","seed_unverified":"One of the April 2026 seed rows, written from our own static page rather than scraped (the same rows as in the layer above). Kept for the audit trail only.","aggregator_result":"A Google News result: a headline behind a redirect, not a source a reader can cite.","self_referential":"The source URL points at magistra.health itself, which is not external evidence.","synthetic_source":"The source is labelled as aggregated reports rather than one citable source.","no_citable_url":"The row has no web link to its source.","rate_out_of_range":"The stored rate is below 0% or above 100%.","placebo_comparator_arm":"A placebo arm's own stated rate from a placebo-controlled trial — kept for a future within-trial risk-difference figure, never pooled as a drug's rate."},"note":"Three layers. intake: the daily pipeline's collect step, summed over every committed run report (agents/data/data/pipeline-<date>.json) plus the latest run. scrapedItems are items read from sources; extractedRows are side-effect rows the extraction model returned after the effect and drug gates (one item can yield several rows, so this is not a count of items); newStored are rows written to the store. duplicateRows = extractedRows - newStored, rows whose dedupe identity (source URL, effect, trial arm, MedDRA term, table) was already stored or repeated in the same run; deduplication is the only filter between the two steps. Why items yielded no row, and per-source counts, were not recorded before 2026-10-04; runs from then carry drops and bySource (runsWithDropDetail counts them). reconciliation: netChangeOutsideDailyRuns is the change to the store made outside the daily collect step (for example one-off repairs, re-collections and removals), not itemised in the run reports. intake reads the run reports in the repository; storage and pooling read the live store, so storage.stored can differ slightly from intake.reconciliation.storedAfterLastRun. storage: stored points vs points counted in totalDataPoints; seed_unverified are the April 2026 seed rows written from our own page, off_taxonomy are rows in extraction categories that no page displays (listed in offTaxonomyByEffect). pooling: per tracked effect, the clinical/regulatory rows behind rateBase.clinical on ?q=effect&id=<id>, how many were pooled into the rate and why the rest were not (keys glossed in poolingReasonGloss); communityTrackRows are user-report and news rows, which feed the separate reporting frequency and are never pooled into a rate."},"dataPointsBySource":{"news":366,"user_report":412,"regulatory":62,"clinical":2679},"dataPointsByEffect":{"nausea":551,"diarrhea":418,"constipation":363,"reduced_appetite":322,"headache":273,"pancreatitis":70,"fatigue":197,"vomiting":434,"abdominal_pain":292,"acid_reflux":155,"gallstones":94,"hair_loss":57,"injection_site_reaction":61,"dizziness":195,"emotional_blunting":37},"lastScraped":"2026-10-30T05:49:06.020Z","drugsTracked":["semaglutide","tirzepatide","liraglutide","retatrutide","orforglipron","survodutide","dulaglutide","exenatide","lixisenatide"],"effectsTracked":[{"id":"nausea","name":"Nausea","severity":"mild","clinicalRateLow":0.15,"clinicalRateMedium":0.28,"clinicalRateHigh":0.4,"corpusClinical":{"ratePct":20.6,"ciLowPct":6,"ciHighPct":52,"statedRates":251,"distinctSources":86,"sourceEntries":86,"seriousAeSources":0,"rateKindNote":"","rateKindNoteNl":"","intervalBasis":"sampling_plus_between_study","intervalNote":"","intervalNoteNl":"","confidence":"very_high","sourceDiversity":"very_high","phaseMix":{"PHASE3":70,"PHASE4":4,"PHASE1":7,"PHASE2":3}},"reportingFrequency":{"mentions":14,"distinctReports":42,"sharePct":33.3,"platforms":["reddit.com","drugs.com"],"note":"Share of distinct community reports (one row per source URL) that mention this effect. Counts only reports hosted on the community platform itself, and — corrected 2026-08-29 — only Reddit posts from the GLP-1, weight-management and diabetes subreddits we collect from: the scraper's subreddit restriction was not holding, and 159 of the previous 185 reports were posts matched on a symptom word in unrelated communities (r/gallbladders, r/AskDocs, r/pregnant). Widened 2026-09-25: ten GLP-1 drug communities the configured list had omitted (r/mounjarouk, r/TirzepatideRX, r/Retatrutide and seven others) were added to it, taking the denominator from 26 to 42. News-aggregator results are excluded, see platforms. The remaining base is small and cannot currently grow (Reddit has blocked our collector since 2026-05-28), so read every share with its distinctReports denominator. Not an incidence rate; not comparable to clinicalRates."}},{"id":"diarrhea","name":"Diarrhoea","severity":"mild","clinicalRateLow":0.1,"clinicalRateMedium":0.18,"clinicalRateHigh":0.25,"corpusClinical":{"ratePct":14.8,"ciLowPct":5,"ciHighPct":36,"statedRates":238,"distinctSources":76,"sourceEntries":76,"seriousAeSources":0,"rateKindNote":"","rateKindNoteNl":"","intervalBasis":"sampling_plus_between_study","intervalNote":"","intervalNoteNl":"","confidence":"very_high","sourceDiversity":"very_high","phaseMix":{"PHASE3":65,"PHASE4":3,"PHASE1":6,"PHASE2":2}},"reportingFrequency":{"mentions":12,"distinctReports":42,"sharePct":28.6,"platforms":["reddit.com","drugs.com"],"note":"Share of distinct community reports (one row per source URL) that mention this effect. Counts only reports hosted on the community platform itself, and — corrected 2026-08-29 — only Reddit posts from the GLP-1, weight-management and diabetes subreddits we collect from: the scraper's subreddit restriction was not holding, and 159 of the previous 185 reports were posts matched on a symptom word in unrelated communities (r/gallbladders, r/AskDocs, r/pregnant). Widened 2026-09-25: ten GLP-1 drug communities the configured list had omitted (r/mounjarouk, r/TirzepatideRX, r/Retatrutide and seven others) were added to it, taking the denominator from 26 to 42. News-aggregator results are excluded, see platforms. The remaining base is small and cannot currently grow (Reddit has blocked our collector since 2026-05-28), so read every share with its distinctReports denominator. Not an incidence rate; not comparable to clinicalRates."}},{"id":"constipation","name":"Constipation","severity":"mild","clinicalRateLow":0.05,"clinicalRateMedium":0.12,"clinicalRateHigh":0.18,"corpusClinical":{"ratePct":11.8,"ciLowPct":3,"ciHighPct":39,"statedRates":220,"distinctSources":65,"sourceEntries":65,"seriousAeSources":0,"rateKindNote":"","rateKindNoteNl":"","intervalBasis":"sampling_plus_between_study","intervalNote":"","intervalNoteNl":"","confidence":"very_high","sourceDiversity":"very_high","phaseMix":{"PHASE3":55,"PHASE4":2,"PHASE1":6,"PHASE2":1}},"reportingFrequency":{"mentions":9,"distinctReports":42,"sharePct":21.4,"platforms":["reddit.com","drugs.com"],"note":"Share of distinct community reports (one row per source URL) that mention this effect. Counts only reports hosted on the community platform itself, and — corrected 2026-08-29 — only Reddit posts from the GLP-1, weight-management and diabetes subreddits we collect from: the scraper's subreddit restriction was not holding, and 159 of the previous 185 reports were posts matched on a symptom word in unrelated communities (r/gallbladders, r/AskDocs, r/pregnant). Widened 2026-09-25: ten GLP-1 drug communities the configured list had omitted (r/mounjarouk, r/TirzepatideRX, r/Retatrutide and seven others) were added to it, taking the denominator from 26 to 42. News-aggregator results are excluded, see platforms. The remaining base is small and cannot currently grow (Reddit has blocked our collector since 2026-05-28), so read every share with its distinctReports denominator. Not an incidence rate; not comparable to clinicalRates."}},{"id":"reduced_appetite","name":"Reduced appetite","severity":"mild","clinicalRateLow":0.08,"clinicalRateMedium":0.15,"clinicalRateHigh":0.22,"corpusClinical":{"ratePct":8.6,"ciLowPct":2,"ciHighPct":32,"statedRates":214,"distinctSources":63,"sourceEntries":63,"seriousAeSources":0,"rateKindNote":"","rateKindNoteNl":"","intervalBasis":"sampling_plus_between_study","intervalNote":"","intervalNoteNl":"","confidence":"very_high","sourceDiversity":"very_high","phaseMix":{"PHASE3":52,"PHASE1":6,"PHASE2":1,"PHASE4":3}},"reportingFrequency":{"mentions":13,"distinctReports":42,"sharePct":31,"platforms":["reddit.com","drugs.com"],"note":"Share of distinct community reports (one row per source URL) that mention this effect. Counts only reports hosted on the community platform itself, and — corrected 2026-08-29 — only Reddit posts from the GLP-1, weight-management and diabetes subreddits we collect from: the scraper's subreddit restriction was not holding, and 159 of the previous 185 reports were posts matched on a symptom word in unrelated communities (r/gallbladders, r/AskDocs, r/pregnant). Widened 2026-09-25: ten GLP-1 drug communities the configured list had omitted (r/mounjarouk, r/TirzepatideRX, r/Retatrutide and seven others) were added to it, taking the denominator from 26 to 42. News-aggregator results are excluded, see platforms. The remaining base is small and cannot currently grow (Reddit has blocked our collector since 2026-05-28), so read every share with its distinctReports denominator. Not an incidence rate; not comparable to clinicalRates."}},{"id":"headache","name":"Headache","severity":"mild","clinicalRateLow":0.08,"clinicalRateMedium":0.12,"clinicalRateHigh":0.14,"corpusClinical":{"ratePct":8.5,"ciLowPct":3,"ciHighPct":20,"statedRates":199,"distinctSources":60,"sourceEntries":60,"seriousAeSources":0,"rateKindNote":"","rateKindNoteNl":"","intervalBasis":"sampling_plus_between_study","intervalNote":"","intervalNoteNl":"","confidence":"very_high","sourceDiversity":"very_high","phaseMix":{"PHASE1":6,"PHASE3":50,"PHASE2":1,"PHASE4":3}},"reportingFrequency":{"mentions":4,"distinctReports":42,"sharePct":9.5,"platforms":["reddit.com","drugs.com"],"note":"Share of distinct community reports (one row per source URL) that mention this effect. Counts only reports hosted on the community platform itself, and — corrected 2026-08-29 — only Reddit posts from the GLP-1, weight-management and diabetes subreddits we collect from: the scraper's subreddit restriction was not holding, and 159 of the previous 185 reports were posts matched on a symptom word in unrelated communities (r/gallbladders, r/AskDocs, r/pregnant). Widened 2026-09-25: ten GLP-1 drug communities the configured list had omitted (r/mounjarouk, r/TirzepatideRX, r/Retatrutide and seven others) were added to it, taking the denominator from 26 to 42. News-aggregator results are excluded, see platforms. The remaining base is small and cannot currently grow (Reddit has blocked our collector since 2026-05-28), so read every share with its distinctReports denominator. Not an incidence rate; not comparable to clinicalRates."}},{"id":"pancreatitis","name":"Pancreatitis (rare)","severity":"severe","clinicalRateLow":0.002,"clinicalRateMedium":0.002,"clinicalRateHigh":0.002,"corpusClinical":{"ratePct":0.1,"ciLowPct":0,"ciHighPct":1,"statedRates":13,"distinctSources":4,"sourceEntries":6,"seriousAeSources":2,"rateKindNote":"2 of 4 sources are SERIOUS adverse-event rates from a trial registry's SAE table, which understate all-cause incidence","rateKindNoteNl":"2 van 4 bronnen zijn percentages voor ERNSTIGE bijwerkingen uit de SAE-tabel van een studieregister, wat de incidentie over alle ernstgraden onderschat","intervalBasis":"sampling_plus_between_study","intervalNote":"","intervalNoteNl":"","confidence":"moderate","sourceDiversity":"moderate","phaseMix":{"PHASE3":4}},"reportingFrequency":{"mentions":0,"distinctReports":42,"sharePct":0,"platforms":["reddit.com","drugs.com"],"note":"Share of distinct community reports (one row per source URL) that mention this effect. Counts only reports hosted on the community platform itself, and — corrected 2026-08-29 — only Reddit posts from the GLP-1, weight-management and diabetes subreddits we collect from: the scraper's subreddit restriction was not holding, and 159 of the previous 185 reports were posts matched on a symptom word in unrelated communities (r/gallbladders, r/AskDocs, r/pregnant). Widened 2026-09-25: ten GLP-1 drug communities the configured list had omitted (r/mounjarouk, r/TirzepatideRX, r/Retatrutide and seven others) were added to it, taking the denominator from 26 to 42. News-aggregator results are excluded, see platforms. The remaining base is small and cannot currently grow (Reddit has blocked our collector since 2026-05-28), so read every share with its distinctReports denominator. Not an incidence rate; not comparable to clinicalRates."}},{"id":"fatigue","name":"Fatigue / Low energy","severity":"mild","clinicalRateLow":0.11,"clinicalRateMedium":0.11,"clinicalRateHigh":0.11,"corpusClinical":{"ratePct":6.6,"ciLowPct":1,"ciHighPct":37,"statedRates":113,"distinctSources":35,"sourceEntries":35,"seriousAeSources":0,"rateKindNote":"","rateKindNoteNl":"","intervalBasis":"sampling_plus_between_study","intervalNote":"","intervalNoteNl":"","confidence":"very_high","sourceDiversity":"very_high","phaseMix":{"PHASE3":29,"PHASE2":2,"PHASE1":2,"PHASE4":2}},"reportingFrequency":{"mentions":6,"distinctReports":42,"sharePct":14.3,"platforms":["reddit.com","drugs.com"],"note":"Share of distinct community reports (one row per source URL) that mention this effect. Counts only reports hosted on the community platform itself, and — corrected 2026-08-29 — only Reddit posts from the GLP-1, weight-management and diabetes subreddits we collect from: the scraper's subreddit restriction was not holding, and 159 of the previous 185 reports were posts matched on a symptom word in unrelated communities (r/gallbladders, r/AskDocs, r/pregnant). Widened 2026-09-25: ten GLP-1 drug communities the configured list had omitted (r/mounjarouk, r/TirzepatideRX, r/Retatrutide and seven others) were added to it, taking the denominator from 26 to 42. News-aggregator results are excluded, see platforms. The remaining base is small and cannot currently grow (Reddit has blocked our collector since 2026-05-28), so read every share with its distinctReports denominator. Not an incidence rate; not comparable to clinicalRates."}},{"id":"vomiting","name":"Vomiting","severity":"moderate","clinicalRateLow":0.03,"clinicalRateMedium":0.05,"clinicalRateHigh":0.08,"corpusClinical":{"ratePct":10.5,"ciLowPct":3,"ciHighPct":28,"statedRates":237,"distinctSources":76,"sourceEntries":76,"seriousAeSources":0,"rateKindNote":"","rateKindNoteNl":"","intervalBasis":"sampling_plus_between_study","intervalNote":"","intervalNoteNl":"","confidence":"very_high","sourceDiversity":"very_high","phaseMix":{"PHASE4":3,"PHASE1":7,"PHASE3":63,"PHASE2":2}},"reportingFrequency":{"mentions":15,"distinctReports":42,"sharePct":35.7,"platforms":["reddit.com","drugs.com"],"note":"Share of distinct community reports (one row per source URL) that mention this effect. Counts only reports hosted on the community platform itself, and — corrected 2026-08-29 — only Reddit posts from the GLP-1, weight-management and diabetes subreddits we collect from: the scraper's subreddit restriction was not holding, and 159 of the previous 185 reports were posts matched on a symptom word in unrelated communities (r/gallbladders, r/AskDocs, r/pregnant). Widened 2026-09-25: ten GLP-1 drug communities the configured list had omitted (r/mounjarouk, r/TirzepatideRX, r/Retatrutide and seven others) were added to it, taking the denominator from 26 to 42. News-aggregator results are excluded, see platforms. The remaining base is small and cannot currently grow (Reddit has blocked our collector since 2026-05-28), so read every share with its distinctReports denominator. Not an incidence rate; not comparable to clinicalRates."}},{"id":"abdominal_pain","name":"Abdominal pain","severity":"moderate","clinicalRateLow":0.03,"clinicalRateMedium":0.05,"clinicalRateHigh":0.07,"corpusClinical":{"ratePct":5.8,"ciLowPct":2,"ciHighPct":19,"statedRates":173,"distinctSources":43,"sourceEntries":43,"seriousAeSources":0,"rateKindNote":"","rateKindNoteNl":"","intervalBasis":"sampling_plus_between_study","intervalNote":"","intervalNoteNl":"","confidence":"very_high","sourceDiversity":"very_high","phaseMix":{"PHASE3":34,"PHASE2":2,"PHASE1":6,"PHASE4":1}},"reportingFrequency":{"mentions":8,"distinctReports":42,"sharePct":19,"platforms":["reddit.com","drugs.com"],"note":"Share of distinct community reports (one row per source URL) that mention this effect. Counts only reports hosted on the community platform itself, and — corrected 2026-08-29 — only Reddit posts from the GLP-1, weight-management and diabetes subreddits we collect from: the scraper's subreddit restriction was not holding, and 159 of the previous 185 reports were posts matched on a symptom word in unrelated communities (r/gallbladders, r/AskDocs, r/pregnant). Widened 2026-09-25: ten GLP-1 drug communities the configured list had omitted (r/mounjarouk, r/TirzepatideRX, r/Retatrutide and seven others) were added to it, taking the denominator from 26 to 42. News-aggregator results are excluded, see platforms. The remaining base is small and cannot currently grow (Reddit has blocked our collector since 2026-05-28), so read every share with its distinctReports denominator. Not an incidence rate; not comparable to clinicalRates."}},{"id":"acid_reflux","name":"Acid reflux (GERD)","severity":"mild","clinicalRateLow":0.03,"clinicalRateMedium":0.05,"clinicalRateHigh":0.08,"corpusClinical":{"ratePct":5.1,"ciLowPct":3,"ciHighPct":10,"statedRates":86,"distinctSources":28,"sourceEntries":28,"seriousAeSources":0,"rateKindNote":"","rateKindNoteNl":"","intervalBasis":"sampling_plus_between_study","intervalNote":"","intervalNoteNl":"","confidence":"very_high","sourceDiversity":"very_high","phaseMix":{"PHASE3":25,"PHASE2":1,"PHASE4":1,"PHASE1":1}},"reportingFrequency":{"mentions":8,"distinctReports":42,"sharePct":19,"platforms":["reddit.com","drugs.com"],"note":"Share of distinct community reports (one row per source URL) that mention this effect. Counts only reports hosted on the community platform itself, and — corrected 2026-08-29 — only Reddit posts from the GLP-1, weight-management and diabetes subreddits we collect from: the scraper's subreddit restriction was not holding, and 159 of the previous 185 reports were posts matched on a symptom word in unrelated communities (r/gallbladders, r/AskDocs, r/pregnant). Widened 2026-09-25: ten GLP-1 drug communities the configured list had omitted (r/mounjarouk, r/TirzepatideRX, r/Retatrutide and seven others) were added to it, taking the denominator from 26 to 42. News-aggregator results are excluded, see platforms. The remaining base is small and cannot currently grow (Reddit has blocked our collector since 2026-05-28), so read every share with its distinctReports denominator. Not an incidence rate; not comparable to clinicalRates."}},{"id":"gallstones","name":"Gallstones (cholelithiasis)","severity":"severe","clinicalRateLow":0.008,"clinicalRateMedium":0.015,"clinicalRateHigh":0.026,"corpusClinical":{"ratePct":1.7,"ciLowPct":0,"ciHighPct":8,"statedRates":37,"distinctSources":14,"sourceEntries":17,"seriousAeSources":3,"rateKindNote":"3 of 14 sources are SERIOUS adverse-event rates from a trial registry's SAE table, which understate all-cause incidence","rateKindNoteNl":"3 van 14 bronnen zijn percentages voor ERNSTIGE bijwerkingen uit de SAE-tabel van een studieregister, wat de incidentie over alle ernstgraden onderschat","intervalBasis":"sampling_plus_between_study","intervalNote":"","intervalNoteNl":"","confidence":"high","sourceDiversity":"high","phaseMix":{"PHASE3":13}},"reportingFrequency":{"mentions":4,"distinctReports":42,"sharePct":9.5,"platforms":["reddit.com","drugs.com"],"note":"Share of distinct community reports (one row per source URL) that mention this effect. Counts only reports hosted on the community platform itself, and — corrected 2026-08-29 — only Reddit posts from the GLP-1, weight-management and diabetes subreddits we collect from: the scraper's subreddit restriction was not holding, and 159 of the previous 185 reports were posts matched on a symptom word in unrelated communities (r/gallbladders, r/AskDocs, r/pregnant). Widened 2026-09-25: ten GLP-1 drug communities the configured list had omitted (r/mounjarouk, r/TirzepatideRX, r/Retatrutide and seven others) were added to it, taking the denominator from 26 to 42. News-aggregator results are excluded, see platforms. The remaining base is small and cannot currently grow (Reddit has blocked our collector since 2026-05-28), so read every share with its distinctReports denominator. Not an incidence rate; not comparable to clinicalRates."}},{"id":"hair_loss","name":"Hair loss (thinning)","severity":"mild","clinicalRateLow":0.03,"clinicalRateMedium":0.03,"clinicalRateHigh":0.03,"corpusClinical":{"ratePct":5,"ciLowPct":2,"ciHighPct":11,"statedRates":22,"distinctSources":11,"sourceEntries":11,"seriousAeSources":0,"rateKindNote":"","rateKindNoteNl":"","intervalBasis":"sampling_plus_between_study","intervalNote":"","intervalNoteNl":"","confidence":"high","sourceDiversity":"high","phaseMix":{"PHASE3":9,"PHASE4":1}},"reportingFrequency":{"mentions":1,"distinctReports":42,"sharePct":2.4,"platforms":["reddit.com","drugs.com"],"note":"Share of distinct community reports (one row per source URL) that mention this effect. Counts only reports hosted on the community platform itself, and — corrected 2026-08-29 — only Reddit posts from the GLP-1, weight-management and diabetes subreddits we collect from: the scraper's subreddit restriction was not holding, and 159 of the previous 185 reports were posts matched on a symptom word in unrelated communities (r/gallbladders, r/AskDocs, r/pregnant). Widened 2026-09-25: ten GLP-1 drug communities the configured list had omitted (r/mounjarouk, r/TirzepatideRX, r/Retatrutide and seven others) were added to it, taking the denominator from 26 to 42. News-aggregator results are excluded, see platforms. The remaining base is small and cannot currently grow (Reddit has blocked our collector since 2026-05-28), so read every share with its distinctReports denominator. Not an incidence rate; not comparable to clinicalRates."}},{"id":"injection_site_reaction","name":"Injection site reaction","severity":"mild","clinicalRateLow":0.03,"clinicalRateMedium":0.04,"clinicalRateHigh":0.05,"corpusClinical":{"ratePct":4.5,"ciLowPct":1,"ciHighPct":15,"statedRates":20,"distinctSources":9,"sourceEntries":9,"seriousAeSources":0,"rateKindNote":"","rateKindNoteNl":"","intervalBasis":"sampling_plus_between_study","intervalNote":"","intervalNoteNl":"","confidence":"moderate","sourceDiversity":"moderate","phaseMix":{"PHASE3":8,"PHASE2":1}},"reportingFrequency":{"mentions":12,"distinctReports":42,"sharePct":28.6,"platforms":["reddit.com","drugs.com"],"note":"Share of distinct community reports (one row per source URL) that mention this effect. Counts only reports hosted on the community platform itself, and — corrected 2026-08-29 — only Reddit posts from the GLP-1, weight-management and diabetes subreddits we collect from: the scraper's subreddit restriction was not holding, and 159 of the previous 185 reports were posts matched on a symptom word in unrelated communities (r/gallbladders, r/AskDocs, r/pregnant). Widened 2026-09-25: ten GLP-1 drug communities the configured list had omitted (r/mounjarouk, r/TirzepatideRX, r/Retatrutide and seven others) were added to it, taking the denominator from 26 to 42. News-aggregator results are excluded, see platforms. The remaining base is small and cannot currently grow (Reddit has blocked our collector since 2026-05-28), so read every share with its distinctReports denominator. Not an incidence rate; not comparable to clinicalRates."}},{"id":"dizziness","name":"Dizziness","severity":"mild","clinicalRateLow":0.08,"clinicalRateMedium":0.08,"clinicalRateHigh":0.08,"corpusClinical":{"ratePct":6.8,"ciLowPct":3,"ciHighPct":15,"statedRates":138,"distinctSources":42,"sourceEntries":42,"seriousAeSources":0,"rateKindNote":"","rateKindNoteNl":"","intervalBasis":"sampling_plus_between_study","intervalNote":"","intervalNoteNl":"","confidence":"very_high","sourceDiversity":"very_high","phaseMix":{"PHASE3":35,"PHASE2":2,"PHASE1":4,"PHASE4":1}},"reportingFrequency":{"mentions":3,"distinctReports":42,"sharePct":7.1,"platforms":["reddit.com","drugs.com"],"note":"Share of distinct community reports (one row per source URL) that mention this effect. Counts only reports hosted on the community platform itself, and — corrected 2026-08-29 — only Reddit posts from the GLP-1, weight-management and diabetes subreddits we collect from: the scraper's subreddit restriction was not holding, and 159 of the previous 185 reports were posts matched on a symptom word in unrelated communities (r/gallbladders, r/AskDocs, r/pregnant). Widened 2026-09-25: ten GLP-1 drug communities the configured list had omitted (r/mounjarouk, r/TirzepatideRX, r/Retatrutide and seven others) were added to it, taking the denominator from 26 to 42. News-aggregator results are excluded, see platforms. The remaining base is small and cannot currently grow (Reddit has blocked our collector since 2026-05-28), so read every share with its distinctReports denominator. Not an incidence rate; not comparable to clinicalRates."}},{"id":"emotional_blunting","name":"Emotional blunting / Reduced pleasure","severity":"moderate","clinicalRateLow":null,"clinicalRateMedium":null,"clinicalRateHigh":null,"clinicalRatesWithdrawn":true,"corpusClinical":null,"reportingFrequency":{"mentions":1,"distinctReports":42,"sharePct":2.4,"platforms":["reddit.com","drugs.com"],"note":"Share of distinct community reports (one row per source URL) that mention this effect. Counts only reports hosted on the community platform itself, and — corrected 2026-08-29 — only Reddit posts from the GLP-1, weight-management and diabetes subreddits we collect from: the scraper's subreddit restriction was not holding, and 159 of the previous 185 reports were posts matched on a symptom word in unrelated communities (r/gallbladders, r/AskDocs, r/pregnant). Widened 2026-09-25: ten GLP-1 drug communities the configured list had omitted (r/mounjarouk, r/TirzepatideRX, r/Retatrutide and seven others) were added to it, taking the denominator from 26 to 42. News-aggregator results are excluded, see platforms. The remaining base is small and cannot currently grow (Reddit has blocked our collector since 2026-05-28), so read every share with its distinctReports denominator. Not an incidence rate; not comparable to clinicalRates."}}],"clinicalRatesNote":"A fixed reference table dated 2026-04-12, not derived from this corpus and carrying no per-effect citation of its own — see `sources` on ?q=effect&id=<id> for what was recorded behind each effect. It reaches published numbers two ways. (1) As the sole clinical base for an effect with no eligible corpus rate point — exactly the effects whose pooled corpus estimate is null (corpusClinical here, rateBase.clinical.pooledEstimate on the per-effect endpoint); the predictor marks these isFallback: true. (2) Since 2026-08-28, as a dose-tier rescale ratio applied to the corpus's OWN pooled rate wherever that tier's pooled clinical records are mostly dose-untagged; isFallback stays false in that case, and the predictor's clinical.basis states both endpoints and the dose-tag denominator while clinical.pooledPercentage carries the corpus rate before any adjustment. Full per-source detail: rateBase.clinical via ?q=effect&id=<id>. WITHDRAWN 2026-09-03 (decision literature-fallback-clinical-rate-2026-08-28, option c) for emotional_blunting only: this table had no rate-stating source at all for it, so its clinicalRate fields are null here and its predictor track carries `available: false` with no percentage — see clinicalRatesWithdrawn on ?q=effect&id=emotional_blunting. RE-SOURCED 2026-09-03 (same decision, option b) for fatigue only: its three tier values are one figure, 0.11, from the FDA Wegovy prescribing information revised 06/2026 (Table 3: fatigue incl. asthenia 11% on 2.4 mg, N=2,116, vs 5% placebo, N=1,261; URL in its sources) — the label reports no per-dose-tier rate, so no gradient is published for it, and it is a semaglutide figure applied at every dose tier regardless of molecule, as this whole table is. RE-SOURCED 2026-09-04 (decision pancreatitis-hairloss-dizziness-triple-derivation-2026-09-03) for hair_loss, dizziness and pancreatitis: their 2026-04-12 triples (1–3%, 2–5%, 0.5–1.2%) had no recorded derivation and their cited trial pages state no such figures; each is now one value at every tier from the same FDA Wegovy label — hair_loss 0.03 (Table 3: 3% on 2.4 mg, N=2,116, vs 1% placebo), dizziness 0.08 (Table 3: 8% vs 4%), and pancreatitis 0.002, which is NOT a proportion of patients like every other value in this table but the label's incidence RATE of 0.2 acute-pancreatitis cases per 100 patient-years of Wegovy exposure (4 adjudicated cases vs 1 on placebo, section 6.1 Adverse Reactions, under Other Adverse Reactions in Adults and/or Pediatric Patients; the section 5.2 warning of the same name states no figure) — read it with that unit. Figures served before 2026-09-04 for these three effects should not be cited.","confidenceNote":"`sourceDiversity` (formerly `confidence`, kept as a deprecated alias with the same value) measures SOURCE DIVERSITY, not precision: it is derived only from distinctSources (≤1 very_low, ≤3 low, ≤9 moderate, ≤24 high, ≥25 very_high) and is computed without reference to the confidence interval. It can read `moderate` on an estimate whose interval spans nearly the whole range — always read ciLowPct/ciHighPct alongside it, and treat a wide interval as the binding statement about how well we know the rate. The converse does NOT hold, and until 2026-09-11 nothing here said so: a NARROW interval is not evidence of a well-known rate. τ² (the between-study heterogeneity term) is 0 by construction when a single source entry contributes, so such an estimate publishes that one study's sampling interval and nothing else — read `intervalBasis` on every pooled block (`sampling_only_single_source` vs `sampling_plus_between_study`, with `intervalNote`/`intervalNoteNl` spelling it out) before reading a tight range as precision.","samplingNote":"Registry sampling bias, disclosed 2026-09-10 and corrected 2026-09-16: registry rows collected before 2026-09-10 through the rotation path were capped at the five highest-percentage arm rows per trial, which selects on the rate being measured (19 of the 25 trials with stored registry rows at the time; the six pinned pivotal trials — SURMOUNT-1, SELECT, STEP 1, STEP 2, SURPASS-CVOT, retatrutide phase 2 — were never affected). The collector was fixed 2026-09-10 and the 19 trials were re-collected in full between 2026-09-10 and 2026-09-16 (every tracked non-placebo arm row the registry posts is stored, verified against the live registry on 2026-09-16), so each study's entry in a pooled estimate is now the mean of every arm the registry posts for that term, not of its five highest. Method, per-trial measurements and the correction record: §4 Limitations and correction-log items 25 and 32 of the published methodology, https://github.com/saurabhgoyal75/magistra-predictor/blob/main/preprint/magistra-methodology.md.","armOverlapNote":"Repeated participants behind the row COUNT, restated 2026-09-26 for the corpus state deployed to production that day (1,286 eligible stated rates; first measured against production 2026-09-21). The flagged-study list itself was last re-verified live against ClinicalTrials.gov on 2026-09-26 by the cycle that deployed this corpus state; the count and percentage figures below are re-derived from that same corpus, not a fresh production query. `statedRates` counts stored rate rows, and a registry row is one ARM of one trial — so a crossover or dose-escalation study whose periods the registry posts as separate event groups over the SAME people contributes several rows for one cohort. The test needs no judgement and cannot false-positive: sum the at-risk denominators of the arms we store for one study and one effect, and if that sum exceeds the trial's own posted enrolment, some participants sit inside more than one of our rows. The same 6 of now 37 registry studies with live rated rows fail it — NCT05841238 (11.5x), NCT06440980 (7.1x), NCT03929744 (2.2x), NCT06370728 (1.9x), NCT05891496 (1.4x), NCT05086445 (1.1x); all six are completed studies posting an ACTUAL enrolment, so the denominator of the test is a final count and not a target — and 726 of 1,278 live registry rate rows (56.8%) come from them, which is 726 of the 1,286 eligible stated rates this site publishes site-wide (56.5%). It does NOT move the percentages: one-entry-per-source collapsing plus sample-size weighting mean that excluding all six changes every published pooled estimate by at most 0.2 percentage points (nausea, fatigue, abdominal_pain and dizziness). It does move the n, and now for only one effect the source-diversity grade, very_high -> high: without those six studies headache reads 49 rates / 22 studies instead of 135/28. (The 2026-09-24 reading was 62.7% of 1,158 rows, at most 0.6 points, and five grade changes — nausea, vomiting, diarrhea, constipation and reduced_appetite very_high -> high. A registry batch stored 2026-09-26 (SCALE Obesity and Prediabetes, REWIND, ELIXA, LEADER, and the rest of SURMOUNT-2 — none of the five among the flagged six) added enough independent sources to those five effects that none still depends on the six for its grade; only headache still does.) Read statedRates as “rate rows we hold”, never as “independent observations”, and read the interval as the statement about how well the rate is known. Both measurement scripts are published for inspection in the methodology mirror (https://github.com/saurabhgoyal75/magistra-predictor/tree/main/methodology) — they read our own store, so they are the audit trail rather than something a reader can run, but the test above needs nothing from us: every flagged study's arms and its posted enrolment are in the ClinicalTrials.gov record whose URL `sources` already gives you.","dataSources":[{"source":"ClinicalTrials.gov (API v2)","points":2429,"lastSeen":"2026-10-30","stale":false},{"source":"Health news (Google News RSS)","points":364,"lastSeen":"2026-10-28","stale":false},{"source":"Reddit (26 subreddits)","points":363,"lastSeen":"2026-05-28","stale":true},{"source":"PubMed / PMC (NCBI E-utilities)","points":243,"lastSeen":"2026-10-29","stale":false},{"source":"FDA FAERS (openFDA API)","points":62,"lastSeen":"2026-08-13","stale":true},{"source":"Drugs.com patient reviews","points":49,"lastSeen":"2026-08-12","stale":true},{"source":"Journal & institutional pages","points":5,"lastSeen":"2026-04-12","stale":true},{"source":"medRxiv / bioRxiv preprints","points":3,"lastSeen":"2026-09-20","stale":true}],"dataSourcesNote":"Derived from the live corpus, scoped to the 15 publicly-tracked effects. `points` is how many data points that source has contributed; `stale: true` means no new point in 30+ days (the collector is blocked, rate-limited or retired).","trialsCited":["SURMOUNT-1 (NEJM 2022)","SELECT (NEJM 2023)"],"apiDocs":{"overview":"/api/data?q=overview","effectDetail":"/api/data?q=effect&id=nausea","countries":"/api/data/countries","bulkAccess":"https://magistra.health/en/data-api (purchased CSV export, full corpus with source URLs)"},"citation":"Magistra Health. GLP-1 Safety & Efficacy Database. magistra.health. Accessed 2026-10-30","license":"Free for research and journalism with attribution (Magistra, magistra.health); no redistribution of the dataset. Bulk export and commercial use via the research subscription.","licenseUrl":"https://magistra.health/en/data#licence","aggregateRatesTable":{"description":"The effectsTracked rate/CI/n/distinctSources figures above, as a standalone per-effect summary table.","license":"https://creativecommons.org/licenses/by/4.0/","csv":"https://magistra.health/data/glp1-aggregate-rates.csv","json":"https://magistra.health/data/glp1-aggregate-rates.json"},"contact":"saurabh@magistra.health"}